We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04718896
Previous Study | Return to List | Next Study

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis (BE CONNECTED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04718896
Recruitment Status : Active, not recruiting
First Posted : January 22, 2021
Last Update Posted : August 23, 2022
Sponsor:
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma SRL )

Brief Summary:
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).

Condition or disease Intervention/treatment Phase
Moderate to Severe Plaque Psoriasis Drug: bimekizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
Actual Study Start Date : April 6, 2021
Estimated Primary Completion Date : April 3, 2025
Estimated Study Completion Date : April 3, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Bimekizumab Dose A
Study participants randomized to this arm will receive bimekizumab (BKZ) Dose A at pre-specified time points during the study.
Drug: bimekizumab
Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
Other Names:
  • BKZ
  • UCB4940

Experimental: Bimekizumab Dose B
Study participants randomized to this arm will receive bimekizumab (BKZ) Dose B at pre-specified time points during the study.
Drug: bimekizumab
Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
Other Names:
  • BKZ
  • UCB4940




Primary Outcome Measures :
  1. Plasma concentration of bimekizumab at Week 0 [ Time Frame: Baseline (Week 0) ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 0.

  2. Plasma concentration of bimekizumab at Week 1 [ Time Frame: Week 1 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 1.

  3. Plasma concentration of bimekizumab at Week 4 [ Time Frame: Week 4 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 4.

  4. Plasma concentration of bimekizumab at Week 8 [ Time Frame: Week 8 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 8.

  5. Plasma concentration of bimekizumab at Week 12 [ Time Frame: Week 12 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 12.

  6. Plasma concentration of bimekizumab at Week 16 [ Time Frame: Week 16 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 16.

  7. Plasma concentration of bimekizumab at Week 20 [ Time Frame: Week 20 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 20.

  8. Plasma concentration of bimekizumab at Week 36 [ Time Frame: Week 36 ]
    Blood samples will be collected at pre-specified time points at Week 36 to determine the bimekizumab plasma concentration, if participant is not eligible for the Open-label Extension (OLE) Period at Week 20 or does not wish to continue into the OLE Period.

  9. Plasma concentration of bimekizumab at Week 40 [ Time Frame: Week 40 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 40.

  10. Plasma concentration of bimekizumab at Week 64 [ Time Frame: Week 64 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 64.

  11. Plasma concentration of bimekizumab at Week 88 [ Time Frame: Week 88 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 88.

  12. Plasma concentration of bimekizumab at Week 112 [ Time Frame: Week 112 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 112.

  13. Plasma concentration of bimekizumab at Week 124 [ Time Frame: Week 124 ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 124.

  14. Plasma concentration of bimekizumab at safety follow up (SFU) [ Time Frame: Week 140 (SFU) ]
    Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 140 (SFU).


Secondary Outcome Measures :
  1. Percentage of participants with treatment-emergent adverse events (TEAEs) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)] ]
    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks.

  2. Percentage of participants with serious TEAEs [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]

    An serious adverse event (SAE) must meet 1 or more of the following criteria:

    • Results in death
    • Is life-threatening
    • Requires inpatient hospitalization or prolongation of existing hospitalization
    • Results in persistent disability/incapacity
    • Is a congenital anomaly/birth defect
    • Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious.

    Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks.


  3. Percentage of participants with TEAEs leading to discontinuation of investigational medicinal product (IMP) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks. This measure considers any TEAE leading to permanent discontinuation of IMP regardless of reason.

  4. Percentage of participants with selected safety topics of interest [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Selected safety topics of interest (including infection [serious, opportunistic, fungal, and tuberculosis (TB)], inflammatory bowel disease [IBD], and injection site reactions) with onset occurring from day of first dose through 20 weeks after final dose of IMP adjusted by duration of participant exposure to IMP.

  5. Change from Baseline in vital signs (systolic and diastolic blood pressure) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Blood pressure will be measured in millimeters of mercury (mmHg).

  6. Change from Baseline in vital signs (heart rate or pulse rate) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Heart rate will be measured in beats per minute (beats/min).

  7. Change from Baseline in vital signs (temperature) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Temperature (oral, axillary, otic or non-contact forehead) will be measured in degrees Celsius (°C).

  8. Change from Baseline in physical examination findings reported as TEAEs with onset occurring from day of first dose through 20 weeks after final dose of IMP [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Clinically significant findings or worsening of previous findings since the physical examination at Baseline will be reported as TEAEs with onset occurring from day of first dose through 20 weeks after final dose of IMP.

  9. Change from Baseline in hematology parameters (platelet count) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Platelets will be measured in number of platelets per liter (10^9/L).

  10. Change from Baseline in hematology parameters (mean corpuscular hemoglobin) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Mean corpuscular hemoglobin (HGB) will be measured in picograms (pg).

  11. Change from Baseline in hematology parameters (mean corpuscular volume) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Mean corpuscular volume will be measured in femtolitres (fL).

  12. Change from Baseline in hematology parameters (erythrocytes) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Erythrocytes will be measured in number of red blood cells per liter (10^12/L).

  13. Change from Baseline in hematology parameters (hemoglobin) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Hemoglobin will be measured in grams per liter (g/L).

  14. Change from Baseline in hematology parameters (hematocrit) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Hematocrit will be measured in volume percentage (%) of red blood cells in blood.

  15. Change from Baseline in clinical chemistry parameters (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase will be measured in units per liter (U/L).

  16. Change from Baseline in hematology parameters (basophils, eosinophils, lymphocytes, monocytes, neutrophils, leukocytes) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Basophils, eosinophils, lymphocytes, monocytes, neutrophils and leukocytes will be measured in number of white blood cells per liter (10^9/L)

  17. Change from Baseline in clinical chemistry parameters (calcium, potassium, sodium, blood urea nitrogen, glucose (nonfasting)) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Calcium, potassium, sodium, blood urea nitrogen, and glucose (non fasting) will be measured in millimoles per liter (mmol/L).

  18. Change from Baseline in clinical chemistry parameters (creatinine, total and direct bilirubin) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Creatinine and bilirubin will be measured in micromols per liter (μmol/L).

  19. Change from Baseline in clinical chemistry parameters (total protein) [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Total protein will be measured in milligrams per liters (mg/L).

  20. Change from Baseline in height [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Growth assessment, as assessed by the change from Baseline in height.

  21. Change from Baseline in weight [ Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140) ]
    Growth assessment, as assessed by the change from Baseline in weight.

  22. Percentage of participants with Psoriasis Area and Severity Index (PASI) 90 response at Week 16 [ Time Frame: Week 16 ]
    The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

  23. Percentage of participants with Investigator's Global Assessment (IGA) 0/1 (Clear [0]/Almost Clear [1] with at least 2-category improvement from Baseline) response at Week 16 [ Time Frame: Week 16 ]

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.

    IGA response (Clear or Almost Clear) is defined as clear [0] or almost clear [1] with at least a two-category improvement from Baseline.


  24. Percentage of participants with Psoriasis Area and Severity Index (PASI) 75 response at Week 4 [ Time Frame: Week 4 ]
    The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

  25. Percentage of participants with anti-bimekizumab antibody (AbAb) detection prior to investigational medicinal product (IMP) administration [ Time Frame: Baseline (Week 0) ]
    Anti-bimekizumab antibody (AbAb) detection prior to investigational medicinal product (IMP) administration

  26. Percentage of participants with anti-bimekizumab antibody (AbAb) detection following investigational medicinal product (IMP) administration [ Time Frame: From Week 1 through 20 weeks after final dose of IMP (up to Week 140) ]
    Anti-bimekizumab antibody (AbAb) detection following investigational medicinal product (IMP) administration

  27. Change from Baseline in Children's Dermatology Life Quality Index (CDLQI) response at Week 16 [ Time Frame: Week 16, compared to Baseline ]
    The CDLQI is a questionnaire designed to measure the impact of skin diseases on the lives of children. The questionnaire consists of 10 questions that are based on the experiences of children with skin disease. The instrument asks participants about symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment. The questions relate to the impact of the skin disease on the child over the last week, (ie, over the last 7 days). The CDLQI total score ranges from 0 to 30 with higher scores indicating higher impact of skin disease on quality of life (Qol).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant must be ≥12 to <18 years of age at the time of signing the informed consent/assent according to local regulation
  • Participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit and:

    1. Body surface area (BSA) affected by PSO ≥10%
    2. Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)
    3. Psoriasis Area and Severity Index (PASI) score ≥12 OR
    4. PASI score ≥10 plus at least 1 of the following:

    i. Clinically relevant facial involvement ii. Clinically relevant genital involvement iii. Clinically relevant hand and foot involvement

  • Participant must be candidate for systemic PSO therapy and/or photo/chemotherapy
  • Body weight ≥30 kg and body mass index for age percentile of ≥5 at Baseline
  • Male or female A female participant will be eligible to participate if she is not pregnant, not breastfeeding, and a woman of childbearing potential (WOCBP) agrees to follow the contraceptive guidance
  • Capable of giving/having parent(s) or legal representative provide signed informed consent/assent (where appropriate)

Exclusion Criteria:

  • Participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO
  • Participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD
  • History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
  • Participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)
  • Participant has laboratory abnormalities at Screening
  • Participant has experienced primary failure to one or more interleukin-17 (IL-17) biologic response modifier OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier
  • Presence of active suicidal ideation, or positive suicide behavior
  • Participant has been diagnosed with severe depression in the past 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04718896


Locations
Layout table for location information
United States, Indiana
Ps0020 50344
Indianapolis, Indiana, United States, 46250
United States, Texas
Ps0020 50359
Cypress, Texas, United States, 77433
Canada
Ps0020 50354
Calgary, Canada
Ps0020 50357
St. John's, Canada
Germany
Ps0020 40645
Frankfurt, Germany
Poland
Ps0020 40626
Bialystok, Poland
Ps0020 40625
Lodz, Poland
Ps0020 40396
Rzeszow, Poland
Ps0020 40335
Warszawa, Poland
Ps0020 40333
Wroclaw, Poland
Ps0020 40334
Wroclaw, Poland
Sponsors and Collaborators
UCB Biopharma SRL
Investigators
Layout table for investigator information
Study Director: UCB Cares 001 844 599 2273 (UCB)
Layout table for additonal information
Responsible Party: UCB Biopharma SRL
ClinicalTrials.gov Identifier: NCT04718896    
Other Study ID Numbers: PS0020
2020-001724-34 ( EudraCT Number )
First Posted: January 22, 2021    Key Record Dates
Last Update Posted: August 23, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access Criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
URL: http://www.Vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by UCB Pharma ( UCB Biopharma SRL ):
bimekizumab
BKZ
adolescent study participants
psoriasis
PSO
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases